Abstract:
Presently provided are inhibitors of cellularly expressed TD02 and IDO1, and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
Abstract:
A compound of formula I: stereoisomers or a pharmaceutically acceptable salt thereof, wherein X, X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are described herein, compositions including the compounds and methods of making and using the compounds for the treatment of diseases.
Abstract:
A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
Abstract:
Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.
Abstract:
A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
Abstract:
A method of applying a label (12) to an article (10), the method comprising : - providing an article having a surface comprising at least one compound curve (16); - providing a label comprising (i) a heat shrinkable film having an inner surface and an outer surface; and (ii) a layer of pressure sensitive adhesive on the inner surface of the heat shrinkable film, wherein the label has a first edge and a contact region,- - contacting the adhesive layer in the contact region of the label with the article; - and applying heat and pressure simultaneously to the label in a direction from the contact region to the first edge such that the first edge of the label adheres to the article and the label shrinks to conform to the compound curve of the article, wherein the heat and pressure are applied by at least one hot air knife assembly comprising a source of heated air, a flow control mechanism and one or more hot air slots.
Abstract:
A rigid or semi-rigid package or container comprising a body, a cover, and a resealable closure. The body may have a tray or cup-like structure defining an interior region for housing one or more items. The tray includes a reclosure section defined by perforated or die-cut punch line(s). A resealable label is disposed along the outer surface of the tray and overlies the reclosure section. The label is releasably attached to the outer tray surface in at least a portion of an area along the perimeter of the reclosure section. The label is sufficiently adhered to at least a portion of the reclosure section such that the reclosure section remains attached to the label when the label is peeled away from the outer tray surface to uncover an opening in the body and allow access to the interior of the container.
Abstract:
Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.